Supplementary Table 1 from Sintilimab plus Anlotinib in Patients with Pretreated Locally Advanced or Metastatic Sarcoma: A Prospective, Single-Arm, Phase II Clinical Trial
Resveratrol shows potent anti-tumor therapeutic properties in various tumors. However, the exact effect of resveratrol on osteosarcoma cells, especially cancer stem cells, remains unclear. In this stu
Ewing Sarcoma (ES) poses a significant therapeutic challenge due to the difficulty in targeting its mainoncodriver, EWS::FLI1. We show that pharmacological targeting of the EWS::FLI1 transcriptionalco
We found the feasibility of targeting TNIK in osteosarcoma. Here, we describe the effects of pharmacological inhibition of TNIK in osteosarcoma cell lines.
We report the effects of 6 and 12 hour 5 nM exposure vs 1 hour 25nM exposure of lurbinectedin on two DSRCT cell lines. Overall design: Evaluation of continuous 5nM and 25 nM transient exposure to lurb
Fibrosarcomas are soft tissue mesenchymal tumors originating from transformed fibroblasts. Fibroblast growth factor-2 (FGF2) and its tyrosine-kinase receptors (FGFRs) play pivotal roles in fibrosarcom
